Literature DB >> 27338743

Fasciocutaneous Lotus Petal Flap for Perineal Wound Reconstruction after Extralevator Abdominoperineal Excision: Application for Reconstruction of the Pelvic Floor and Creation of a Neovagina.

Joke Hellinga1, Patrick C K H Khoe1, Boudewijn van Etten2, Patrick H J Hemmer2, Klaas Havenga2, Martin W Stenekes1, Yassir Eltahir3.   

Abstract

BACKGROUND: The extralevator abdominoperineal excision (ELAPE) procedure creates an extensive soft tissue defect of the pelvic floor. It has been suggested that primary reconstruction reduces the risk of wound infection and delayed wound healing in this high-risk area. Use of myocutaneous flaps or omentoplasty are associated with functional limitations and complications. We performed the perineal variant of the lotus petal flap, which was originally described for vulvar reconstruction. We aimed to verify if application of the lotus petal flap in pelvic floor reconstruction after ELAPE meets the goals of an ideal reconstruction.
METHODS: We performed a retrospective study of 28 patients who underwent the lotus petal flap procedure for pelvic floor reconstruction after ELAPE between January 2011 and March 2014.
RESULTS: Median age was 62.1 years and 78.6 % of patients were female. In most patients the tumor was preoperatively irradiated (89.3 %) and in 28.6 % of the reconstructions a biological mesh was applied. No total flap loss occurred. Six (21.4 %) patients had no complications, while 13 (46.4 %) patients had minor complications (Clavien-Dindo grade I-II). Reoperation (Clavien-Dindo grade IIIb) was performed in nine patients (32.1 %), three of whom required a second lotus petal flap reconstruction. Median time until wound healing was 14 weeks. No additional surgery was performed for aesthetic problems.
CONCLUSIONS: Reconstruction of the pelvic floor after ELAPE using the fasciocutaneous lotus petal flap has limited major complications, but still with a high incidence of minor wound complications. This retrospective cohort study shows limited consequences on form and function.

Entities:  

Mesh:

Year:  2016        PMID: 27338743     DOI: 10.1245/s10434-016-5332-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  Fasciocutaneous lotus petal flap in the treatment of chronic pouch-vaginal fistula in ulcerative colitis.

Authors:  L Sofo; A E Potenza; D Cervelli; F Sacchetti; N Ursino
Journal:  Tech Coloproctol       Date:  2018-12-03       Impact factor: 3.781

Review 2.  Extralevator abdominoperineal excision for advanced low rectal cancer: Where to go.

Authors:  Yu Tao; Jia-Gang Han; Zhen-Jun Wang
Journal:  World J Gastroenterol       Date:  2020-06-14       Impact factor: 5.742

3.  Gender-specific Anatomical Distribution of Internal Pudendal Artery Perforator: A Radiographic Study for Perineal Reconstruction.

Authors:  Regina Sonda; Andrea Monticelli; Erica Dalla Venezia; Chiara Giraudo; Giorgio Giatsidis; Franco Bassetto; Veronica Macchi; Cesare Tiengo
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-10-29

4.  Long-term outcomes of laparoscopic Extralevator Abdominoperineal excision with modified position change for low rectal Cancer treatment.

Authors:  Shaowei Sun; Shengbo Sun; Xiangyun Zheng; Jiangtao Yu; Wenchang Wang; Qing Gong; Guowei Zhao; Jing Li; Huanhu Zhang
Journal:  BMC Cancer       Date:  2022-08-24       Impact factor: 4.638

5.  Aesthetic Outcomes of Perineal Reconstruction with the Lotus Petal Flap.

Authors:  Joke Hellinga; Joke Fleer; Berend van der Lei; Paul M N Werker; Boudewijn van Etten; Martin W Stenekes
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-06-10

6.  A low incidence of perineal hernia when using a biological mesh after extralevator abdominoperineal excision with or without pelvic exenteration or distal sacral resection in locally advanced rectal cancer patients.

Authors:  E A Dijkstra; N L E Kahmann; P H J Hemmer; K Havenga; B van Etten
Journal:  Tech Coloproctol       Date:  2020-06-08       Impact factor: 3.781

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.